Table 4 Patient and tumor characteristics according to tacrolimus intra-patient variability status in patients with hepatocellular carcinoma.
Characteristics | Low tacrolimus IPV | High tacrolimus IPV | P |
|---|---|---|---|
(CV ≤ 30%, n = 243) | (CV > 30%, n = 106) | ||
Age, years | 55.3 ± 6.7 | 55.8 ± 7.2 | 0.518 |
Female sex, n (%) | 46 (18.9) | 19 (17.9) | 0.824 |
Underlying liver disease, n (%) | 0.542 | ||
Alcoholic | 15 (6.2) | 11 (10.4) | |
Hepatitis B | 196 (80.7) | 80 (75.5) | |
Hepatitis C | 24 (9.9) | 7 (6.6) | |
Others | 8 (3.3) | 8 (7.5) | |
MELD Na score | 16.5 ± 6.9 | 16.4 ± 7.0 | 0.962 |
Body mass index, kg/m2 | 24.2 ± 3.1 | 24.1 ± 3.3 | 0.717 |
Deceased donor, n (%) | 62 (25.5) | 26 (24.5) | 0.845 |
Donor age, y | 35.2 ± 13.0 | 35.1 ± 12.4 | 0.933 |
Donor female sex, n (%) | 94 (38.7) | 34 (32.1) | 0.239 |
Donor graft steatosis | |||
Macrosteatosis, % | 1 (0–5) | 5 (0–5) | 0.417 |
Microsteatosis, % | 2 (0–5) | 1 (0–5) | 0.434 |
Mean tacrolimus level, ng/mL | 6.9 ± 1.8 | 6.1 ± 2.1 | < 0.001 |
Tacrolimus IPV, CV % | 20.4 ± 5.2 | 41.9 ± 11.2 | < 0.001 |
mTOR inhibitor, n (%) | 59 (24.3) | 51 (48.1) | < 0.001 |
Mean mTOR inhibitor level, ng/mL | 3.7 ± 1.4 | 4.3 ± 1.4 | 0.025 |
Pre-transplantation AFP, IU/mL | 6.9 (3.5, 29.5) | 7.6 (3.2, 25.3) | 0.64 |
AFP > 100 IU/mL, n (%) | 27 (11.1) | 11 (10.5) | 0.862 |
Microvascular invasion, n (%) | 55 (22.8) | 31 (29.5) | 0.185 |
Viable tumor number | 1.0 (1.0, 3.0) | 2.0 (1.0, 4.0) | 0.217 |
Maximum tumor size, cm | 2.1 ± 1.7 | 2.3 ± 1.8 | 0.428 |
Tumor differentiation, n (%) | 0.2 | ||
Well | 27 (11.1) | 10 (9.4) | |
Moderate | 104 (42.8) | 35 (33.0) | |
Poor | 74 (30.5) | 44 (41.5) | |
Complete tumor necrosis | 38 (15.6) | 17 (16.0) | |
Loco-regional treatment, n (%) | 169 (69.5) | 92 (77.4) | 0.135 |
TACE | 95 | 34 | |
RFA | 14 | 8 | |
TACE + RFA | 35 | 18 | |
Combined treatments | 25 | 32 | |
Number of loco-regional treatment | 0.255 | ||
1 | 64 | 28 | |
2 | 40 | 14 | |
3 or more | 65 | 40 | |
